Haverford Trust Co Buys 4,763 Shares of Stryker Co. (NYSE:SYK)

Haverford Trust Co raised its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 212,048 shares of the medical technology company's stock after acquiring an additional 4,763 shares during the quarter. Haverford Trust Co owned approximately 0.06% of Stryker worth $76,604,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. International Assets Investment Management LLC lifted its holdings in shares of Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock valued at $308,433,000 after purchasing an additional 852,496 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Stryker by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company's stock worth $3,096,078,000 after acquiring an additional 813,311 shares during the period. 1832 Asset Management L.P. grew its holdings in shares of Stryker by 146.9% in the 1st quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company's stock worth $314,449,000 after acquiring an additional 522,817 shares during the period. American Century Companies Inc. grew its holdings in shares of Stryker by 287.6% in the 2nd quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company's stock worth $172,033,000 after acquiring an additional 375,166 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Stryker by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 31,459,393 shares of the medical technology company's stock worth $11,258,373,000 after acquiring an additional 309,592 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SYK. UBS Group increased their target price on Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. BTIG Research increased their target price on Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Barclays increased their price target on Stryker from $402.00 to $418.00 and gave the stock an "overweight" rating in a research note on Thursday, October 31st. Piper Sandler reissued an "overweight" rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their price target on Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, Stryker has an average rating of "Moderate Buy" and an average target price of $393.65.

Stryker Price Performance

Shares of SYK stock traded up $1.40 during trading hours on Wednesday, reaching $388.51. 791,622 shares of the company were exchanged, compared to its average volume of 1,252,837. Stryker Co. has a fifty-two week low of $282.35 and a fifty-two week high of $390.59. The stock's fifty day moving average is $362.38 and its two-hundred day moving average is $346.42. The company has a market cap of $148.11 billion, a price-to-earnings ratio of 41.47, a P/E/G ratio of 2.92 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the prior year, the business earned $2.46 earnings per share. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. Sell-side analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock worth $24,825,275 over the last ninety days. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.